Recombinant Mal d 1 is a reliable diagnostic tool for birch pollen allergen-associated apple allergy

被引：16
|
作者：
Kollmann, Dagmar [1 ]
Geroldinger-Simic, Marija [1 ]
Kinaciyan, Tamar [2 ]
Huber, Hans [3 ]
Ebner, Christof [4 ]
Lidholm, Jonas [5 ]
Bohle, Barbara [1 ]
机构：
[1] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Christian Doppler Lab Immunomodulat, Vienna, Austria
[2] Med Univ Vienna, Dept Dermatol, DIAID, Vienna, Austria
[3] Biomay AG, Vienna, Austria
[4] Allergy Clin, Vienna, Austria
[5] Thermo Fisher Sci, Uppsala, Sweden
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2013年 / 132卷 / 04期
基金：
奥地利科学基金会;
关键词：
IN-VIVO; IMMUNOTHERAPY; TESTS;
D O I：
10.1016/j.jaci.2013.05.030
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：1008 / 1010
页数：4
相关论文
共 50 条
  • [1] Sublingual immunotherapy with recombinant Mal d 1 improves birch pollen-associated apple allergy
    Kinaciyan, T.
    Nagl, B.
    Faustmann, S.
    Frommlet, F.
    Kopp, S.
    Wolkersdorfer, M.
    Huber, H.
    Bohle, B.
    ALLERGY, 2017, 72 : 145 - 145
  • [2] Recombinant Mal d 1 facilitates sublingual challenge tests of birch pollen-allergic patients with apple allergy
    Kinaciyan, T.
    Nagl, B.
    Faustmann, S.
    Kopp, S.
    Wolkersdorfer, M.
    Bohle, B.
    ALLERGY, 2016, 71 (02) : 272 - 274
  • [3] The optimal recombinant allergen for treatment of birch allergy should contain characteristics of both Bet v 1 and Mal d 1, the major apple allergen
    Würtzen, PA
    Lund, L
    Hansen, L
    Millner, AH
    Ferreras, M
    Holm, J
    Ipsen, H
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2005, 115 (04) : 894 - 894
  • [4] Pollen-related food allergy: cloning and immunological analysis of isoforms and mutants of Mal d 1, the major apple allergen, and Bet v 1, the major birch pollen allergen
    Son, DY
    Scheurer, S
    Hoffmann, A
    Haustein, D
    Vieths, S
    EUROPEAN JOURNAL OF NUTRITION, 1999, 38 (04) : 201 - 215
  • [5] Pollen-related food allergy: cloning and immunological analysis of isoforms and mutants of Mal d 1, the major apple allergen, and Bet v 1, the major birch pollen allergen
    D.Y. Son
    S. Scheurer
    A. Hoffmann
    D. Haustein
    S. Vieths
    European Journal of Nutrition, 1999, 38 : 201 - 215
  • [6] Birch pollen immunotherapy inhibits anaphylaxis to the cross-reactive apple allergen Mal d 1 in mice
    Utsch, L.
    Logiantara, A.
    Wallner, M.
    Hofer, H.
    van Ree, R.
    van Rijt, L. S.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2016, 46 (11): : 1474 - 1483
  • [7] Purification and Characterization of Recombinant Expressed Apple Allergen Mal d 1
    Kaeswurm, Julia A. H.
    Nestl, Bettina
    Richter, Sven M.
    Emperle, Max
    Buchweitz, Maria
    METHODS AND PROTOCOLS, 2021, 4 (01) : 1 - 14
  • [8] The Effect of Birch Pollen Immunotherapy on Apple and rMal d 1 Challenges in Adults with Apple Allergy
    van der Valk, Johanna
    Nagl, Birgit
    van Wljk, Roy Gerth
    Bohle, Barbara
    de Jong, Nicolette
    NUTRIENTS, 2020, 12 (02)
  • [9] Diagnostic value of the allergen, Pru p 1 in adult patients with birch pollen-associated oral allergy syndrome
    Hwang, Eui-Kyung
    Kim, Joo-Hee
    Nam, Young-Hee
    Jin, Hyun Jung
    Park, Hae-Sim
    ALLERGY, 2011, 66 (12) : 1621 - 1622
  • [10] Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells
    Fritsch, R
    Bohle, B
    Vollmann, U
    Wiedermann, U
    Jahn-Schmid, B
    Krebitz, M
    Breiteneder, H
    Kraft, D
    Ebner, C
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (04) : 679 - 686
12345